|
Orthologous residues
|
|
PAK2 (human): T402‑p, PAK2 (mouse): T402‑p, PAK2 (rat): T402‑p, PAK2 (rabbit): T402‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
electrophoretic mobility shift, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
neutrophil
|
|
Cellular systems studied:
primary cells
|
|
Species studied:
guinea pig
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
PHOSPHATASE
|
PPP2CA (mouse)
|
pharmacological inhibitor of upstream enzyme
|
|
|
PHOSPHATASE
|
PPP2CB (mouse)
|
pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
fMLP
|
|
|
|
increase
|
|
|
okadaic acid
|
fMLP
|
|
|
augment treatment-induced increase
|
|
|
ascomycin
|
fMLP
|
|
|
augment treatment-induced increase
|
|
|
fMLP, cyclosporin A
|
fMLP
|
|
|
augment treatment-induced increase
|
|
|
FK506
|
fMLP
|
|
|
augment treatment-induced increase
|
|
|